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Survivin, encoded by BIRC5 gene (baculoviral IAP repeat containing 5), belongs to the family of inhibitors of apoptosis proteins
(IAPs). In mammalian cells it participates in the control of mitosis, apoptosis regulation, and cellular stress response. Its expression
is increased in almost all types of cancers. The aim of this study was to investigate the role of BIRC5 polymorphisms in
breast cancer (BC) and to connect survivin expression with various clinicopathological characteristics of BC patients. Blood
and archival tumour tissue samples were collected from 26 BC patients from Croatia. Survivin expression was determined
immunohistochemically. BIRC5 promoter, coding region, and 3’UTR were genotyped. DNA from 74 healthy women was used
as control. BIRC5 polymorphisms and survivin expression were tested against age of onset, histological grade, tumour type
and size, lymph node status, oestrogen, progesterone, Her2, and Ki67 status. Numbers of samples with weak, moderate, and
strong survivin expression were 9 (33.3%), 11 (40.7%), and 7 (25.9%), respectively. Most patients had nuclear survivin staining
(92.6%). High survivin expression was significantly associated with negative oestrogen receptor status (p=0.007) and positive Ki67
expression (p=0.032). Ki67 expression was also positively correlated with histological grade (p=0.0009). Fourteen polymorphisms
were found in BC samples, located mostly in promoter and 3’UTR of BIRC5. There was no significant difference in the distribution
of polymorphisms between BC and control samples. Among clinicopathological characteristics of BC patients, alleles of five BIRC5
polymorphisms were associated with younger age of onset: c.-644T>C (55.8 years [y] vs. 48.1 y; p=0.006), c.-241C>T (54.2 y vs.
45.0; p=0.029), c.9809T>C (55.8 y vs. 48.1 y; p=0.006), c.-1547C>T (58.3 y vs. 50.9 y; p=0.011), and c.9386T>C (50.8 y vs. 59.5 y;
p=0.004). To assess the significance of BIRC5 polymorphisms and survivin expression as predictive and prognostic biomarkers for
BC further research with a larger sample size is needed.
1. Introduction
Breast cancer (BC) is one of the most common malignancies
among women worldwide. Despite generally good prognosis
for BC patients, there is a wide variation in survival [1].
Some of the common risk factors for BC include age, genetic
background, hormonal factors, reproductive and menstrual
history, excessive alcohol consumption, radiation, benign
breast disease, and obesity [2]. Genetic variation has been
shown to affect both susceptibility and prognosis of BC
[1]. Genome wide association studies (GWAS) have recently
been used to identify new loci for BC, and so far almost
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100 loci have been identified [2]. In addition to providing
new prognostic markers, genetic determinants of prognosis
can also give new biological insight for progression of BC
[3]. Survivin, encoded by BIRC5 (baculoviral IAP repeat
containing 5) gene, belongs to the family of inhibitors of
apoptosis (IAP) proteins [4]. It is the smallest of eight IAP
proteins and contains a single Baculovirus IAP Repeat (BIR),
which is the hallmark of these molecules [5, 6]. Survivin is
a multifunctional protein and in mammalian cells it partici-
pates in at least three cellular processes: the control ofmitosis,
the regulation of apoptosis, and the cellular stress response
[5]. Survivin is strongly expressed during development, while
in healthy organisms it is not expressed in differentiated
tissues, and its expression is markedly increased in almost
all types of cancers (including bladder cancer, lung cancer,
breast cancer, stomach, oesophagus, pancreas, liver, uterine,
ovarian, and haematological cancers) [7]. Elevated expression
of survivin in BC is associated with increased resistance
to chemo- and radiotherapy, increased grade, lymph node
invasion, and tumour size, as well as decreased survival rate
[8]. According to Marsicano et al., breast cancer patients
with higher expression of BIRC5 have significantly greater
chance of developing metastasis than patients with lower
expression [9]. Survivin is expressed in a cell cycle-regulated
manner, being maximally expressed during the G2/M phase,
followed by rapid decline of both the mRNA and protein
levels at the G1 phase [10]. Several BIRC5 polymorphisms
were shown to be associated with susceptibility (gastric [11],
bladder [12], and hepatocellular [13]), survival (colorectal
[14] and breast [15]), or age of onset (ovarian cancer [4]).
Some of these polymorphisms create binding sites for either
transcription factors or regulatory miRNA and potentially
can influence survivin levels. Survivin has been proposed
as a potential target for anticancer intervention and several
survivin inhibitors and survivin-related molecular therapies
are in development [16]. The purpose of this preliminary
study was to investigate the role of BIRC5 polymorphisms
in BC. The connection between polymorphisms found and
protein expression in tumour tissue and their association was
also assessed.
2. Materials and Methods
2.1. Study Subjects. This study included BC patients who
had their regular check-up at the Eljuga Polyclinic and
agreed to participate. Upon signing the consent forms their
blood was drawn. 26 patients, diagnosed between 2000 and
2012 and whose archival paraffin embedded tumour tissue
was available from archive at the University Hospital for
Tumours, University Hospital Centre “Sestre Milosrdnice,”
were included in the study. One patient had a bilateral BC
and both tumours were available for testing. Demographic
and clinicopathological data on patients was collected from
medical records. Demographic characteristics included age
of onset and time since operation, and clinicopathologi-
cal characteristics included histological grade, tumour size,
oestrogen and progesterone receptor status, Her2 status,
lymph node status, type, and Ki67 status (determined rou-
tinely as part of the diagnostic procedure in the clinic). Two
5-𝜇m sections of tumour tissue were cut from paraffin block
for immunohistochemical analysis. DNA samples from 74
healthy women with no history of BC (median age 80, range
65-101) were collected in our previous study [17]. Although
usual case-control studies are age matched, in this case it was
more appropriate to use elderly healthy population as control.
This population is less likely to have cancer predisposing
polymorphisms. The study was approved by the Institutional
Ethics Committee (EP-6820/13-11).
2.2. Immunohistochemical Staining. Survivin protein was
analysed as follows: slides were deparaffinized, prewarmed in
Epitope Retrieval Solution (Dako, Glostrup, Denmark) and
kept at 95-99∘C for 20 min, left to cool for additional 20 min,
and then washed in PBS 3x5 min. Endogenous peroxidase
was blocked with 3 % H
2
O
2
/methanol for 10 min and then
washed 3x5 min in PBS.The sample was circled by PAP-PEN
(Kiyota, Baltimore, MD). Protein block serum-free (DAKO)
was added for 10 min.
Immunohistochemical staining was performed using
monoclonal rabbit anti-survivin antibody (1:200, 71G4B7,
Cell Signalling Technology, Danvers, MA). Following an
overnight incubation, the immunodetection was completed
using the LSAB Visualization System (DAKO) utilizing 3, 3-
diaminobenzidine (DAB) chromogen as substrate, according
to the manufacturer’s instructions. All sections were counter-
stained with haematoxylin (DAKO). Negative controls were
obtained by omitting the primary antibody.
Stained slides were examined by two experienced pathol-
ogists. Sampleswere scored between 1 and 3 based on survivin
expression, taking into account the percentage of positive
cells and the staining intensity, as previously described by
Xu et al. [18]. Staining intensity was expressed as + (weak),
++ (moderate), and +++ (intense). Percentage of tumor cells
positive for survivin stainingwas categorized as 0 (no positive
cells), 1 (<10 %), 2 (10-50 %), and 3 (>50 %). Final score was
then generated by multiplying the staining intensity with the
percentage of positive cells and ranged from 0 (no stained
tumor cells) to 9 (>50 % of intensively stained tumor cells).
The final score of 0 was considered as negative (0), 1-3 as weak
(1), 4-6 as moderate (2), and 7-9 points as strong (3).
2.3. SNP Selection and Genotyping. Whole coding region of
the BIRC5 gene (including alternative exons 2alpha, 2B, and
3B) was genotyped, including the most common SNPs in
BIRC5 promoter and the 3’ untranslated region (3’UTR).
Polymorphisms that were selected from the National Cen-
ter for Biotechnology Information SNPdatabase (http://www
.ncbi.nlm.nih.gov/snp) are those usually used in association
studies (see [4, 10, 13–15, 19–21]).Themajority of these studies
have found that polymorphisms in 5’ and 3’ regions have
the greatest impact on survivin expression [22] and might
contribute to risk of various cancers [21]. Genomic DNA
from blood was extracted by the salting out method. Thir-
teen PCR fragments were analysed using high resolution
melting analysis on High-Resolution Melter (HR-1, Idaho
Technology, USA) as described by Cvok et al. [17] followed
by Sanger sequencing (ABI PRISM 310 Genetic Analyzer,
Applied Biosystems, USA). Due to presence of 5 different
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Table 1: Patient clinicopathological characteristics.
Characteristic No. of patients (%)
Age at diagnosis (years)
< 40 1 (3.8)
40-50 9 (34.6)
50-60 8 (30.8)
> 60 8 (30.8)
Years since operation
5 8 (30.8)
10 15 (57.7)
15 3 (11.5)
Histological grade
1 4 (14.8)
2 12 (44.4)
3 10 (37.0)
N.A.∗ 1 (3.7)
Tumour size
1 (≤ 2 cm) 20 (74.1)
2 (> 2 ≤ 5 cm) 6 (22.2)
3 (> 5 cm) 1 (3.7)
Oestrogen receptor status
Positive 21 (77.8)
Negative 6 (22.2)
Progesterone receptor status
Positive 16 (59.3)
Negative 11 (40.7
Her2 status
Positive 2 (7.4)
Negative 22 (81.5)
N.A. 3 (11.1)
Lymph node status
Positive 11 (40.7)
Negative 16 (59.3)
Pathologic Characteristics
Invasive ductal carcinoma 22 (81.5)
Medullary carcinoma 2 (7.4)
Invasive lobular carcinoma 1 (3.7)
Mixed invasive ductal/lobular carcinoma 1 (3.7)
Papillary carcinoma 1 (3.7)
Ki67 status
Positive 12 (44.4)
Negative 12 (44.4)
N.A. 3 (11.1)
∗ Patient data not available.
polymorphisms in the PCR product of exon 4, it was directly
sequenced. PCR primer sequences and cycling conditions are
listed in Supplementary Table 1.
2.4. Statistical Analysis. Genotype and allele frequencies of
patients and controls were compared using 𝜒2 test. Deviation
from the Hardy–Weinberg equilibrium (HWE) and linkage
disequilibrium were calculated using the online tool SHEsis
Table 2: Levels and localization of survivin expression.
Characteristic No. of samples (%)
Survivin immunoreactivity score
weak 9 (33.3)
moderate 11 (40.7)
strong 7 (25.9)
Survivin cellular localization
cytoplasmic 1 (3.7)
nuclear 25 (92.6)
cytoplasmic+nuclear 1 (3.7)
[http://analysis.bio-x.cn/myAnalysis.php] [23]. The 𝜒2 test
was used for testing the association between genetic data
and categorical clinicopathological variables. Independent
samples t-test and one-way analysis of variance with Tukey-
Kramer post hoc test were used for testing the difference
between continuous (age of onset and logarithmic trans-
formed tumour size) and categorical variables. Two-tailed p-
values less than 0.05 were considered statistically significant.
Statistical analysis was performed using MedCalc v18.2.1
(MedCalc Software bvba).
3. Results and Discussion
3.1. Patient Characteristics. A total of 26 patients with BC
were recruited in this study.Themain clinical and histopatho-
logical features are summarized in Table 1. The median age
of patients at diagnosis was 53 years (range 37-69): only
one patient (3.8%) was younger than 40 years, 34.6% were
between 40 and 50 years, 30.8% were between 50 and 60, and
30.8% were older than 60. The majority of patients (96.2%)
were still alive at the end of the study so survival analysis was
not performed.
Tumour size was associated with positive lymph nodes
(p=0.004). Histological grade was associated with Ki67
expression (p=0.0009). All samples with histological grade
1 were negative for Ki67, while only one sample with
histological grade 3 was negative for Ki67. Progesterone
receptor (PR) and oestrogen receptor (ER) status wereweakly
positively associated (0.053). These results are in agreement
with previously published international data [24–27].
3.2. Survivin Expression. Survivin expression was analysed in
27 BC samples from 26 patients using immunohistochemical
staining. Samples were scored between 1 and 3 based on
survivin expression, taking into account the percentage of
positive cells and the staining intensity (Figure 1). The num-
bers of samples exhibiting survivin expression with a score
of 1 (weak), 2 (moderate), and 3 (strong) were 9 (33.34%), 11
(40.72%), and 7 (25.94%), respectively (Table 2).Themajority
of patients had nuclear survivin staining (92.6%), so we com-
bined all the samples together for the statistical evaluation.
The high nuclear staining of survivin is different than
most published data, where the nuclear staining is mostly
lower than cytoplasmic [18, 28–31] and only rarely has been
described as equal or higher than cytoplasmic [32, 33].
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Figure 1: Examples of scored staining intensities: (a) negative control, (b) score 1, (c) score 2, and (d) score 3.
3.3. Association of Survivin Expression with Clinicopatholog-
ical Parameters. Clinicopathological findings (age at diag-
nosis, time since operation, histological grade, tumour size,
oestrogen and progesterone receptors, Her2 status, lymph
node status, and Ki67 status) were compared with the
immunohistochemical characterization of survivin expres-
sion. Since the majority of samples (22 of 27 samples, 84.6%)
were ductal BC all samples were grouped together. The
statistical analyses revealed a significant association between
survivin expression and ER status. High survivin expres-
sion was significantly associated with negative ER status
(p=0.007). No samples with low survivin expression (score
1), 18.2% samples with medium expression (score 2), and
57.1% of samples with high survivin expression (score 3) had
negative ER status (Figure 2). Survivin expression was weakly
associated with negative PR status (p=0.051). Furthermore,
another statistically significant association was confirmed
between survivin expression and Ki67 expression. High sur-
vivin expression was associated with positive Ki67 expression
(p=0.032).
There is controversial data reported about association
between high survivin expression and negative ER and/or PR
status in BC. While some studies [34, 35] found the same
association as here, other studies report these parameters
as not significant [32, 36, 37]. The similar situation is with
the association between high survivin expression and Ki67
expression. While some studies [38] showed the same results
as here, others showed there was no significant association
between survivin and Ki67 [31, 39].
0%
20%
40%
60%
80%
100%
1 2 3
Survivin staining intensity
ER -
ER +
Figure 2: Association between survivin expression and ER status.
Survivin expression was ranked weak, moderate, and strong, and
percentage of ER negative and ER positive samples per group is
shown.
3.4. BIRC5 Polymorphisms in Breast Cancer Patients. Fifteen
different polymorphisms were found in the constitutional
DNA of 26 BC patients and 74 healthy controls.
The whole BIRC5 gene coding region and selected pro-
moter and 3'UTR regions were investigated for selected ten
polymorphisms. One of the ten polymorphisms (c.-235G>A)
was not found in BC patients. Polymorphisms and their
frequencies are listed in Table 3.
According to theTRANSFACdatabase (http://genexplain
.com/transfac), promoter and 5’UTR region of BIRC5 gene
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Table 3: Comparison of minor allele frequencies of BIRC5 polymorphisms between breast cancer patients and healthy control samples.
Nucleotide changes are named according to the literature.
gene region SNP ID number nucleotide change
minor allele
frequency controls
(n/N, %)∗
minor allele
frequency BC samples
(n/N, %)∗
p (for allele
frequencies)
promoter rs3764383 c.-1547C>T∗∗ 37/148 (25.0) 16/52 (30.8) 0.466
promoter rs8073903 c.-644T>C 49/148 (33.1) 18/52 (34.6) 0.865
promoter rs8073069 c.-625G>C 33/148 (22.3) 13/52 (25.0) 0.704
promoter rs17878731 c.-267G>A 1/148 (0.7) 1/52 (1.9) 0.453
promoter rs17878467 c.-241C>T 16/148 (10.8) 6/52 (11.5) 1.000
promoter rs17887126 c.-235G>A 2/148 (1.3) 0/52 (0)
5'UTR rs9904341 c.-31G>C 55/148 (37.2) 18/52 (34.6) 0.867
intron 2 rs4789551 c.221+209T>C 7/148 (4.7) 1/52 (1.9) 0.683
exon 4 rs2071214 c.9194G>A∗ ∗ ∗ 5/148 (3.4) 1/52 (1.9) 1.000
3'UTR rs17885521 c.9288G>C 3/148 (2.0) 1/52 (1.9) 1.000
3'UTR rs17882627 c.9342G>A 2/148 (1.3) 2/52 (3.8) 0.278
3'UTR rs2239680 c.9386T>C 34/148 (23.0) 14/52 (26.9) 0.575
3'UTR rs17882139 c.9387 9388insAA 3/148 (2.0) 2/52 (3.8) 0.606
3'UTR rs1042489 c.9809T>C 53/148 (35.8) 18/52 (34.6) 1.000
3'UTR rs2661694 c.10611C>A 38/148 (25.7) 11/52 (21.1) 0.578
∗ n – number of minor alleles, N – number of analyzed alleles
∗∗C is the minor allele
∗ ∗ ∗G is the minor allele.
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Figure 3: Structure of BIRC5 gene with positions of analyzed polymorphisms. Positions of known binding sites for transcription factors
and miRNA are shown according to TRANSFAC database [40]. Chromosome 17 positions are numbered according to human genome build
GRCh38/hg38.
contain 29 binding sites for 14 different transcription fac-
tors. Chromosome positions of the detected polymorphisms
revealed that polymorphisms rs17878467 (c.-241C>T) and
rs17887126 (c.-235G>A) are located in the shared binding
site of transcription factors EGR1 and SP1 (Figure 3). 3’UTR
region also contains 16 binding sites for 11 different miRNAs,
and only polymorphism rs1042489 (c.9809T>C) is located in
the binding site of hsa-miR-708-5p (Figure 3) [40].
Fourteen different polymorphisms were found in BC
samples while in controls one more polymorphism was
6 Journal of Oncology
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Figure 4: Pairwise linkage disequilibrium (LD) of eight BIRC5 sequence variants with highest minor allele frequency. The location of each
sequence variant along the BIRC5 gene is relative to the real nucleotide position. The number in each diamond indicates the intensity of LD
(r2) between respective pairs of sequence variants. The LD strength is also represented by shades of grey (0 [white] < r2 < 1 [black]). (a)
Controls. (b) Cases.
present (c.-235G>A). The majority of detected polymor-
phisms were located either upstream or downstream of the
coding region of the gene, and only one in the coding region.
In addition to ten polymorphisms selected for this study, five
more rare polymorphisms were found: one in the promoter
(c.-267G>A), one in intron 2 (c.221+209T>C), and 3 in the
3'UTR (c. 9288G>C, c.9342G>A, and c.9387 9388insAA).
There was no significant difference in genotype or allele
frequencies between BC and control samples.
The observed allele frequencies for most of the polymor-
phisms are in accordance with previously observed frequen-
cies for either global or European populations [15, 19, 20, 22,
41–43], or in NCBI database (http://www.ncbi.nlm.nih.gov),
and only for c.221+209T>C the frequency was lower in this
study than previously observed [41, 44]. c.-235G>Apolymor-
phism found only in healthy controls is known to create a new
“alternative” binding site for the transcription factor GATA-1
and is suggested to increase the BC aggressiveness [45]. Since
most of the patients in this study are still alive, it is possible
that this is a reason this polymorphism was not found in the
patient group.
Analysis showed there is a difference in number of
polymorphisms in linkage disequilibrium (LD) between BC
samples and controls. BC cases showed increased nonrandom
association of alleles at multiple loci. In case of c.-644C>T
and c.9809T>C, these two polymorphisms always appear
in the same combination in all tested BC samples showing
complete LD (r2=0.99) (Figure 4). Only one pair of poly-
morphisms, c.9386T>C and c.10611C>A, shows decreased
association in BC samples compared to control samples.
LD between various BIRC5 polymorphisms have often
been reported in different populations: some observed here,
but also others. LD between c.-1547C>T and c.9368 found
here has been reported by Shi et al. [15], as were c.-1547C>T
with c.10611C>A and c.9386T>C with c.10611C>A. The latter
one was also reported by Pu et al. [46]. LD between c.-
644T>C and c.-625G>Cwas reported twice, by Jang et al. [19]
and Yang et al. [42], and between c.-625G>C and c.9809T>C
once [47]. Interestingly, the polymorphisms in total LD, c.-
644C>T and c.9809T>C, found in BC patients have not been
described before.
3.5. Association of BIRC5 Polymorphisms with Survivin
Expression and Clinicopathological Parameters. BIRC5 poly-
morphisms were not associated with survivin expression,
but several polymorphisms were found to be associated with
age of onset. Genotype frequencies of polymorphisms c.-
644T>C, c.9386T>C, and c.9809T>Cwere significantly asso-
ciated with age of onset, while c.-1547C>T was weakly asso-
ciated. Allele frequencies of these four, as well as SNP c.-
241C>T, were also associated with age of onset (Table 4).
When genotype frequencies were plotted against age of onset,
a clear trend could be seen for the five polymorphisms
(Figure 5) (the results are presented as in Han et al.'s study
[4]).
For the c.-1547C>Tpolymorphism, theminor allele Twas
associated with earlier age of onset. The same trend is visible
for the c.-644C>T allele and the c.9089C>T allele, where
in both cases the minor C allele is associated with earlier
age of onset. For the c.9386T>C allele, the major allele T is
associated with earlier age of onset. For the final, c.-241C>T
polymorphism, where the difference was significant only on
allele but not on genotype frequencies, the minor allele T
also seems to be associated with earlier age of onset but the
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Figure 5: Association of age of onset with the significantly associated polymorphisms. (a) c.-1547C>T. (b) c.-644T>C. (c) c.-241C>T. (d)
c.9386T>C. (e) c.9809T>C.
number of samples in the TT group is too low to make this
comparison.
Until now, only two studies showed association between
BIRC5 polymorphisms and age of onset. Han et al. [4] found
significant connection of age of onset for the c.-1547A>G
and less significantly c.-31G>C polymorphisms in ovarian
cancer, while Hmeljak et al. [20] found that c.-241C>T was
associated with the age of diagnosis of malignant pleural
mesothelioma patients, but not with total survival. These
results are comparable with our results in BC, where we
show that the minor allele of the c.1547A>G polymorphism
is also associated with age of onset, and in our case the
results for the c.-241C>T are significant when comparing
allele, but not for genotype frequencies.This discrepancymay
be due to a small number of samples with the TT genotype
(only one in our dataset). In BC, amplifications in BIRC5
gene were also associated with the younger age of onset
[48].
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Table 4: Association of genotype and allele frequencies of polymor-
phisms with age of onset.
polymorphism mean±SD (years) p-value
c.-1547C>T∗ genotype CC 62.3±6.5 0.054
CT 55.8±8.1
TT 49.0±10.1
allele C 58.3±7.9 0.011
T 50.9±9.8
c.-644T>C genotype TT 59.4±8.2 0.006
TC 50.7±8.6
CC 39.0±2.8
allele T 55.8±9.2 0.006
C 48.1±9.1
c.-241C>T genotype CC 54.7±10.0 0.143
CT 49.0±4.5
TT 37.0±0.0
allele C 54.2±9.6 0.029
T 45.0±7.1
c.9386T>C genotype TT 49.1±9.3 0.029
TC 57.4±8.4
CC 62.3±6.5
allele T 50.8±9.6 0.004
C 59.5±7.6
c.9809T>C genotype TT 59.4±8.2 0.006
TC 50.7±8.6
CC 39.0±2.8
allele T 55.8±9.2 0.006
C 48.1±9.1
∗ C is the minor allele.
4. Conclusions
This was the first study investigating the possible role of
BIRC5 polymorphisms in breast cancer etiology conducted
in Croatia. In our study no association of any of BIRC5
polymorphism with BC or level of survivin expression
was observed. High survivin expression was significantly
associated with negative ER status. However, as many as
five BIRC5 polymorphisms were associated with the age of
onset, a phenomenon which was previously observed only in
ovarian cancer patients. Two of those five polymorphisms (c.-
644T>C and c.9809T>C) were also shown to be in complete
LD in breast cancer patients.We are aware that the sample size
of this study was limited, but it should be noted that the allele
frequencies for polymorphisms found were in accordance
with previous reports, except for c.-235G>A, which was not
present in BC samples. To assess the significance of BIRC5
polymorphisms and survivin expression as predictive and
prognostic biomarkers for BC further research with a larger
sample size is needed.
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